Compositions and methods for treating cancer
AssigneeUniversity of Iowa Research Foundation
InventorsMichael K. Schultz, Somya Kapoor, Douglas R. Spitz
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.
Claims14
A combination of a glutathione (GSH) synthesis inhibitor and an anti-cancer composition comprising vemurafenib, whereby the GSH synthesis inhibitor is included in a dosage of from 1.5-17 g/m2 buthionine sulphoximine (BSO).
A kit comprising a GSH synthesis inhibitor, a container, and a package insert or label indicating the administration of the GSH synthesis inhibitor with an anti-cancer composition for treating melanoma, whereby the GSH synthesis inhibitor is buthionine sulphoximine (BSO) in a dosage of from 1.5-17 g/m2, and further providing that the anti-cancer composition comprises vemurafenib.
A method for treating a drug-resistant melanoma in a mammal, comprising administering to the mammal that is resistant to MAPK pathway inhibitor and/or could acquire resistance to MAPK pathway inhibitors a combination of a GSH synthesis inhibitor and vemurafenib, whereby the GSH synthesis inhibitor and the vemurafenib are administered sequentially, and further providing that the GSH synthesis inhibitor comprises buthionine sulphoximine (BSO) in a dosage of from 1.5-17 g/m2.
A method for treating a drug-resistant melanoma in a mammal, comprising administering to the mammal that is resistant to MAPK pathway inhibitor and/or could acquire resistance to MAPK pathway inhibitors a combination of buthionine sulphoximine (BSO) and vemurafenib, and further providing that the BSO is administered in a dosage of from 1.5-17 g/m2.
Dependencies are inferred from the claim text.